文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Orphan drug designation for pracinostat, volasertib and alvocidib in AML.

作者信息

Bose Prithviraj, Grant Steven

机构信息

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA.

出版信息

Leuk Res. 2014 Aug;38(8):862-5. doi: 10.1016/j.leukres.2014.06.007. Epub 2014 Jun 17.

DOI:10.1016/j.leukres.2014.06.007
PMID:24996975
Abstract
摘要

相似文献

[1]
Orphan drug designation for pracinostat, volasertib and alvocidib in AML.

Leuk Res. 2014-8

[2]
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.

Leuk Res. 2015-12

[3]
Emergence of crenolanib for FLT3-mutant AML.

Blood. 2013-11-21

[4]
Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.

Expert Opin Investig Drugs. 2016-6

[5]
Novel drugs for older patients with acute myeloid leukemia.

Leukemia. 2014-8-21

[6]
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.

Oncotarget. 2017-3-28

[7]
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

Blood Adv. 2019-2-26

[8]
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.

J Pharmacol Exp Ther. 2015-3

[9]
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Blood. 2013-9-17

[10]
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.

Expert Opin Investig Drugs. 2014-4-21

引用本文的文献

[1]
Total Synthesis of Rohitukine and Dysoline and Their Anticancer Analogues Flavopiridol and IIIM-290.

ACS Omega. 2025-8-16

[2]
Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy.

J Enzyme Inhib Med Chem. 2025-12

[3]
Detection of Genomic Structural Variations Associated with Drug Sensitivity and Resistance in Acute Leukemia.

Cancers (Basel). 2024-1-18

[4]
Targeting CDK1 in cancer: mechanisms and implications.

NPJ Precis Oncol. 2023-6-13

[5]
Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes.

Molecules. 2023-3-4

[6]
Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia.

Bioact Mater. 2022-9-20

[7]
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.

Leuk Lymphoma. 2021-5

[8]
BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.

J Int Med Res. 2020-5

[9]
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.

Front Oncol. 2019-12-12

[10]
Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy.

Oncotarget. 2019-2-8

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索